Trusted Sources

FENOFIBRATE Questions ? Need a second opinion? Ask Our Health Experts!

Type your question here

 letters left

FENOFIBRATE Safety Reports

Total FENOFIBRATE reports: 194. FENOFIBRATE FDA safety alerts: No. Reported deaths: 17    Reported hospitalizations: 148. Read More Here.

< Previous  Showing 151-194 of 194

Consumer or non-health professional from UNITED STATES reported FENOFIBRATE problem on Dec 30, 2005. Male patient, 76 years of age, was diagnosed with hypercholesterolaemia and was treated with FENOFIBRATE. After drug was administered, patient experienced the following problems/side effects: angiopathy, cerebrovascular accident. FENOFIBRATE dosage: unknown. During the same period patient was treated with CARDURA, ASPIRIN, PLAVIX. Patient was hospitalized. Patient recovered.

FENOFIBRATE problem was reported by a Physician from JAPAN on Apr 12, 2006. Female patient, 66 years of age, was diagnosed with biliary cirrhosis primary and was treated with FENOFIBRATE. After drug was administered, patient experienced the following problems/side effects: abdominal pain upper, alanine aminotransferase increased, anorexia, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood bilirubin increased, c-reactive protein increased, eosinophil count increased, gamma-glutamyltransferase increased. FENOFIBRATE dosage: 150 MG; QD; PO. During the same period patient was treated with URSODIOL. Patient was hospitalized. Patient recovered.

Pharmacist from UNITED STATES reported FENOFIBRATE problem on May 19, 2006. Male patient, weighting 160.0 lb, was diagnosed with blood cholesterol and was treated with FENOFIBRATE. After drug was administered, patient experienced the following problems/side effects: muscle spasms. FENOFIBRATE dosage: unknown. Patient recovered.

FENOFIBRATE problem was reported by a Consumer or non-health professional from FRANCE on May 15, 2006. Male patient, 60 years of age, was diagnosed with dyslipidaemia and was treated with FENOFIBRATE. After drug was administered, patient experienced the following problems/side effects: liver disorder, renal failure acute, rhabdomyolysis. FENOFIBRATE dosage: unknown. During the same period patient was treated with DILTIAZEM, ACEBUTOLOL, ACETYLSALICYLIC ACID SRT, ACETYLSALICYLIC ACID SRT, ALLOPURINOL, GLIBENCLAMIDE. Patient was hospitalized. Patient recovered.

Consumer or non-health professional from FRANCE reported FENOFIBRATE problem on Jan 30, 2006. Male patient, 75 years of age, was diagnosed with hyperlipidaemia, diabetes mellitus non-insulin-dependent, aortic valve replacement, hypertension and was treated with FENOFIBRATE. After drug was administered, patient experienced the following problems/side effects: myopathy. FENOFIBRATE dosage: unknown. During the same period patient was treated with METFORMIN HYDROCHLORIDE, ROSIGLITAZONE, FENPROCOUMON, VALSARTAN. Patient was hospitalized. Patient recovered.

FENOFIBRATE problem was reported by a Health Professional from JAPAN on May 22, 2006. Female patient, 66 years of age, was diagnosed with biliary cirrhosis primary and was treated with FENOFIBRATE. After drug was administered, patient experienced the following problems/side effects: alanine aminotransferase increased, anorexia, antimitochondrial antibody positive, antinuclear antibody positive, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood immunoglobulin m increased, c-reactive protein increased, eosinophilia. FENOFIBRATE dosage: 150 MG, ORAL. During the same period patient was treated with URSODEOXYCHOLIC ACID. Patient recovered.

Consumer or non-health professional from JAPAN reported FENOFIBRATE problem on June 12, 2006. Female patient, 66 years of age, was diagnosed with biliary cirrhosis, hepatic function abnormal and was treated with FENOFIBRATE. After drug was administered, patient experienced the following problems/side effects: abdominal discomfort, anorexia, biliary cirrhosis, eosinophil count increased, granulomatous liver disease, hepatic trauma, lymphocyte stimulation test positive, pyrexia. FENOFIBRATE dosage: 150 MG QDAY PO. During the same period patient was treated with URSODEOXYCHOLIC ACID. Patient was hospitalized. Patient recovered.

FENOFIBRATE problem was reported by a Health Professional from FRANCE on Mar 26, 2002. Female patient, weighting 4.63 lb, was treated with FENOFIBRATE. After drug was administered, patient experienced the following problems/side effects: blood pressure decreased, bradycardia, cardiac murmur, cardiomyopathy, congenital tricuspid valve atresia, cyanosis, heart disease congenital, malaise, metabolic acidosis. FENOFIBRATE dosage: unknown. During the same period patient was treated with ISOPTIN, PENTOXIFYLLINE, FLUOXETINE HYDROCHLORIDE, PERINDOPRIL ERBUMINE, ALPRAZOLAM, DINOPROSTONE, CEFOTAXIME, AMPICILLIN. Patient died on 09/09/1996.

Pharmacist from UNITED STATES reported FENOFIBRATE problem on July 03, 2006. Male patient, weighting 418.4 lb, was diagnosed with hypertriglyceridaemia and was treated with FENOFIBRATE. After drug was administered, patient experienced the following problems/side effects: flushing, hot flush, menopausal symptoms, swelling. FENOFIBRATE dosage: 48 MG Q DAY PO BUCCAL. During the same period patient was treated with CYANOCOBALAMIN, FOLIC ACID, LABETALOL, SYNTHROID, LISINOPRIL, METFORMIN HYDROCHLORIDE, OMEPRAZOLE. Patient recovered.

FENOFIBRATE problem was reported by a Pharmacist from UNITED STATES on June 26, 2006. Female patient was diagnosed with mixed hyperlipidaemia and was treated with FENOFIBRATE. After drug was administered, patient experienced the following problems/side effects: angioneurotic oedema. FENOFIBRATE dosage: 160 MG; QD;. Patient recovered.

Pharmacist from UNITED STATES reported FENOFIBRATE problem on June 26, 2006. Female patient was diagnosed with mixed hyperlipidaemia and was treated with FENOFIBRATE. After drug was administered, patient experienced the following problems/side effects: cholecystectomy. FENOFIBRATE dosage: 160 MG; QD;. Patient recovered.

FENOFIBRATE problem was reported by a Pharmacist from UNITED STATES on June 26, 2006. Female patient was diagnosed with mixed hyperlipidaemia and was treated with FENOFIBRATE. After drug was administered, patient experienced the following problems/side effects: cerebral haemorrhage. FENOFIBRATE dosage: 160 MG; QD;. During the same period patient was treated with EZETIMIBE. Patient died.

Pharmacist from UNITED STATES reported FENOFIBRATE problem on June 26, 2006. Female patient was diagnosed with mixed hyperlipidaemia and was treated with FENOFIBRATE. After drug was administered, patient experienced the following problems/side effects: cholangitis. FENOFIBRATE dosage: 160 MG; QD;. During the same period patient was treated with EZETIMIBE. Patient recovered.

FENOFIBRATE problem was reported by a Consumer or non-health professional from FRANCE on June 29, 2006. Male patient, 53 years of age, weighting 191.8 lb, was diagnosed with dyslipidaemia, diabetes mellitus and was treated with FENOFIBRATE. After drug was administered, patient experienced the following problems/side effects: dehydration, diarrhoea, rhabdomyolysis. FENOFIBRATE dosage: 267.5 MG. During the same period patient was treated with GLICLAZIDE, PERINDOPRIL, BISOPROLOL RPG. Patient was hospitalized. Patient recovered.

Consumer or non-health professional from UNITED STATES reported FENOFIBRATE problem on July 18, 2006. Female patient was diagnosed with mixed hyperlipidaemia and was treated with FENOFIBRATE. After drug was administered, patient experienced the following problems/side effects: cholangitis. FENOFIBRATE dosage: unknown. During the same period patient was treated with EZETIMIBE. Patient recovered.

FENOFIBRATE problem was reported by a Consumer or non-health professional from UNITED STATES on July 18, 2006. Female patient was diagnosed with mixed hyperlipidaemia and was treated with FENOFIBRATE. After drug was administered, patient experienced the following problems/side effects: angioneurotic oedema. FENOFIBRATE dosage: unknown. Patient recovered.

Health Professional from UNITED STATES reported FENOFIBRATE problem on Mar 26, 2002. Female patient, weighting 4.63 lb, was treated with FENOFIBRATE. After drug was administered, patient experienced the following problems/side effects: blood pressure decreased, bradycardia, cardiac murmur, cardiomyopathy, congenital tricuspid valve atresia, cyanosis, heart disease congenital, hypertension neonatal, malaise. FENOFIBRATE dosage: unknown. During the same period patient was treated with ISOPTIN, PENTOXIFYLLINE, FLUOXETINE HYDROCHLORIDE, PERINDOPRIL ERBUMINE, ALPRAZOLAM, ASPIRIN, DINOPROSTONE, CEFOTAXIME. Patient died on 09/09/1996.

FENOFIBRATE problem was reported by a Consumer or non-health professional from UNITED STATES on July 18, 2006. Female patient, 74 years of age, was diagnosed with mixed hyperlipidaemia, gastric ulcer and was treated with FENOFIBRATE. After drug was administered, patient experienced the following problems/side effects: cholangitis acute. FENOFIBRATE dosage: unknown. During the same period patient was treated with EZETIMIBE, DOXAZOSIN MESYLATE, FUROSEMIDE, GLIPIZIDE, METFORMIN, METOPROLOL TARTRATE, PANTOPRAZOLE. Patient was hospitalized. Patient recovered.

Consumer or non-health professional from FRANCE reported FENOFIBRATE problem on July 18, 2006. Female patient, 71 years of age, was diagnosed with mixed hyperlipidaemia and was treated with FENOFIBRATE. After drug was administered, patient experienced the following problems/side effects: cholecystitis, collapse of lung, lung consolidation, pleural effusion. FENOFIBRATE dosage: unknown. During the same period patient was treated with EZETIMIBE, ACETYLSALICYLIC ACID SRT, CELECOXIB, CITALOPRAM HYDROBROMIDE, ESTRADIOL, OXAZEPAM. Patient was hospitalized. Patient recovered.

FENOFIBRATE problem was reported by a Consumer or non-health professional from UNITED STATES on July 18, 2006. Female patient, 57 years of age, was diagnosed with mixed hyperlipidaemia and was treated with FENOFIBRATE. After drug was administered, patient experienced the following problems/side effects: polyarthritis, pulmonary oedema. FENOFIBRATE dosage: unknown. During the same period patient was treated with LEVOTHYROXINE, NICOTINE, ACETAMINOPHEN W, ACETAMINOPHEN W, AMITRIPTYLINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE. Patient was hospitalized. Patient recovered.

Pharmacist from UNITED STATES reported FENOFIBRATE problem on Aug 23, 2006. Female patient, 68 years of age, was diagnosed with hyperlipidaemia and was treated with FENOFIBRATE. After drug was administered, patient experienced the following problems/side effects: blood pressure decreased, dizziness, syncope. FENOFIBRATE dosage: unknown. During the same period patient was treated with VYTORIN. Patient recovered.

FENOFIBRATE problem was reported by a Pharmacist from UNITED STATES on Aug 24, 2006. Male patient, 60 years of age, weighting 154.3 lb, was diagnosed with blood triglycerides increased and was treated with FENOFIBRATE. After drug was administered, patient experienced the following problems/side effects: pancreatitis acute. FENOFIBRATE dosage: 201 MG I D. Patient was hospitalized. Patient recovered.

Consumer or non-health professional from FRANCE reported FENOFIBRATE problem on Aug 22, 2006. Male patient, 53 years of age, was diagnosed with dyslipidaemia, hyperglycaemia and was treated with FENOFIBRATE. After drug was administered, patient experienced the following problems/side effects: dehydration, diabetes mellitus, diarrhoea, renal failure, rhabdomyolysis, weight decreased. FENOFIBRATE dosage: 267.5 MG, QD. During the same period patient was treated with GLICLAZIDE, PERINDOPRIL ERBUMINE, BISOPROLOL FUMARATE. Patient recovered.

FENOFIBRATE problem was reported by a Health Professional from FRANCE on Sept 08, 2006. Female patient, weighting 216.1 lb, was diagnosed with type iii hyperlipidaemia and was treated with FENOFIBRATE. After drug was administered, patient experienced the following problems/side effects: blister, rash, scar. FENOFIBRATE dosage: unknown. During the same period patient was treated with CIPROFIBRATE, BEZAFIBRATE. Patient recovered.

Physician from FRANCE reported FENOFIBRATE problem on Sept 18, 2006. Male patient, 53 years of age, was diagnosed with dyslipidaemia, hyperglycaemia and was treated with FENOFIBRATE. After drug was administered, patient experienced the following problems/side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood triglycerides increased, dehydration, diabetes mellitus, diarrhoea, myalgia, overdose. FENOFIBRATE dosage: 267.5 MG, QD. During the same period patient was treated with GLICLAZIDE, PERINDOPRIL ERBUMINE, BISOPROLOL FUMARATE. Patient recovered.

FENOFIBRATE problem was reported by a Consumer or non-health professional from FRANCE on Sept 12, 2006. Female patient, 60 years of age, was diagnosed with hypertriglyceridaemia, osteoporosis prophylaxis and was treated with FENOFIBRATE. After drug was administered, patient experienced the following problems/side effects: cholestasis, erythema, hepatocellular damage, hepatotoxicity, investigation abnormal. FENOFIBRATE dosage: unknown. During the same period patient was treated with RALOXIFENE. Patient was hospitalized. Patient recovered.

Consumer or non-health professional from FRANCE reported FENOFIBRATE problem on Jan 20, 2006. Male patient, 57 years of age, was diagnosed with type iib hyperlipidaemia and was treated with FENOFIBRATE. After drug was administered, patient experienced the following problems/side effects: becker's muscular dystrophy, blood creatine phosphokinase increased, mitral valve incompetence, myalgia, myopathy toxic, myositis. FENOFIBRATE dosage: unknown. During the same period patient was treated with ATORVASTATIN, INFLUENZA VACCINE, INFLUENZA VACCINE. Patient was hospitalized. Patient recovered.

FENOFIBRATE problem was reported by a Physician from SPAIN on Dec 18, 2006. Female patient, 60 years of age, was diagnosed with hypertriglyceridaemia, osteoporosis, prophylaxis and was treated with FENOFIBRATE. After drug was administered, patient experienced the following problems/side effects: cholelithiasis, cholestasis, chromaturia, hepatic necrosis, hepatocellular damage, jaundice, laboratory test abnormal, lymphocyte percentage decreased, prurigo. FENOFIBRATE dosage: 250 MG Q DAY. During the same period patient was treated with RALOXIFENE. Patient was hospitalized. Patient recovered.

Health Professional from FRANCE reported FENOFIBRATE problem on Jan 12, 2007. Female patient, 36 years of age, was treated with FENOFIBRATE. After drug was administered, patient experienced the following problems/side effects: cervix dystocia. FENOFIBRATE dosage: unknown. During the same period patient was treated with FUROSEMIDE, ENALAPRIL MALEATE, ZOPICLONE. Patient recovered.

FENOFIBRATE problem was reported by a Health Professional from FRANCE on Jan 12, 2007. Female patient, weighting 2.87 lb, was treated with FENOFIBRATE. After drug was administered, patient experienced the following problems/side effects: congenital musculoskeletal anomaly, foetal arrhythmia, hypotension, kidney malformation, low set ears, metabolic acidosis, microcephaly, neonatal respiratory distress syndrome, premature baby. FENOFIBRATE dosage: unknown. Patient died on 07/30/2003.

Consumer or non-health professional from FRANCE reported FENOFIBRATE problem on Jan 12, 2007. Female patient, 65 years of age, was diagnosed with dyslipidaemia, atrial fibrillation, mitral valve replacement and was treated with FENOFIBRATE. After drug was administered, patient experienced the following problems/side effects: haemarthrosis, international normalised ratio increased, melaena, normochromic normocytic anaemia, renal failure acute. FENOFIBRATE dosage: unknown. During the same period patient was treated with WARFARIN. Patient was hospitalized. Patient recovered.

FENOFIBRATE problem was reported by a Consumer or non-health professional from FRANCE on Jan 15, 2007. Female patient, 58 years of age, weighting 167.6 lb, was diagnosed with hypertension and was treated with FENOFIBRATE. After drug was administered, patient experienced the following problems/side effects: pulmonary embolism. FENOFIBRATE dosage: 160 MG, QD. During the same period patient was treated with VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLOR. Patient was hospitalized. Patient recovered.

Health Professional from UNITED KINGDOM reported FENOFIBRATE problem on Jan 09, 2007. Male patient, 72 years of age, was diagnosed with lipids increased, aortic valve replacement and was treated with FENOFIBRATE. After drug was administered, patient experienced the following problems/side effects: international normalised ratio increased. FENOFIBRATE dosage: 160 MG, ORAL. During the same period patient was treated with WARFARIN, BUMETANIDE, CARVEDILOL, DIGOXIN, NOVOMIX, PRAVASTATIN, RAMIPRIL, SPIRONOLACTONE. Patient was hospitalized. Patient recovered.

FENOFIBRATE problem was reported by a Health Professional from AUSTRALIA on Jan 18, 2007. Female patient, 65 years of age, was treated with FENOFIBRATE. After drug was administered, patient experienced the following problems/side effects: atrial fibrillation, cardiomyopathy, coagulopathy, gastrointestinal haemorrhage, haemarthrosis, international normalised ratio increased, normochromic normocytic anaemia, renal failure acute. FENOFIBRATE dosage: unknown. During the same period patient was treated with WARFARIN. Patient was hospitalized and became disabled. Patient recovered.

Health Professional from FRANCE reported FENOFIBRATE problem on Jan 23, 2007. Male patient, 40 years of age, was diagnosed with attention deficit/hyperactivity disorder and was treated with FENOFIBRATE. After drug was administered, patient experienced the following problems/side effects: irritability, mood swings. FENOFIBRATE dosage: unknown. During the same period patient was treated with STRATTERA, METHYLPHENIDATE, CILAZAPRIL. Patient recovered.

FENOFIBRATE problem was reported by a Physician from UNITED KINGDOM on Jan 19, 2007. Female patient, 63 years of age, was treated with FENOFIBRATE. After drug was administered, patient experienced the following problems/side effects: high density lipoprotein decreased. FENOFIBRATE dosage: 160 MG, QD. During the same period patient was treated with ROSIGLITAZONE, ATORVASTATIN CALCIUM, METFORMIN HYDROCHLORIDE. Patient recovered.

Consumer or non-health professional from UNITED KINGDOM reported FENOFIBRATE problem on Jan 19, 2007. Male patient, 52 years of age, weighting 115.7 lb, was treated with FENOFIBRATE. After drug was administered, patient experienced the following problems/side effects: high density lipoprotein decreased. FENOFIBRATE dosage: 160 MG. During the same period patient was treated with ROSIGLITAZONE, GLICLAZIDE, METFORMIN, ATORVASTATIN CALCIUM. Patient recovered.

FENOFIBRATE problem was reported by a Consumer or non-health professional from UNITED KINGDOM on Jan 19, 2007. Male patient, 59 years of age, was treated with FENOFIBRATE. After drug was administered, patient experienced the following problems/side effects: glycosylated haemoglobin decreased, high density lipoprotein decreased. FENOFIBRATE dosage: 160 MG, QD. During the same period patient was treated with ROSIGLITAZONE, METFORMIN, PIOGLITAZONE. Patient recovered.

Consumer or non-health professional from UNITED KINGDOM reported FENOFIBRATE problem on Jan 19, 2007. Male patient, 54 years of age, was treated with FENOFIBRATE. After drug was administered, patient experienced the following problems/side effects: high density lipoprotein decreased. FENOFIBRATE dosage: 160 MG. During the same period patient was treated with ROSIGLITAZONE, METFORMIN, ROSUVASTATIN, PIOGLITAZONE. Patient recovered.

FENOFIBRATE problem was reported by a Physician from UNITED STATES on Feb 05, 2007. Male patient, 53 years of age, was treated with FENOFIBRATE. After drug was administered, patient experienced the following problems/side effects: alanine aminotransferase increased, ammonia increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood bilirubin increased, blood glucose increased, epididymitis, liver injury, somnolence. FENOFIBRATE dosage: unknown. During the same period patient was treated with ISONIAZID, PYRIDOXINE, ACCUPRIL, PENTOXIFYLLINE, FELODIPINE, METOPROLOL SUCCINATE, ZETIA, CIPRO. Patient recovered.

Consumer or non-health professional from AUSTRALIA reported FENOFIBRATE problem on Feb 20, 2007. Female patient, 65 years of age, was diagnosed with dyslipidaemia, atrial fibrillation, skin graft and was treated with FENOFIBRATE. After drug was administered, patient experienced the following problems/side effects: atrial fibrillation, cardiomyopathy, dyslipidaemia, gastrointestinal haemorrhage, haemarthrosis, injury, international normalised ratio increased, normochromic normocytic anaemia. FENOFIBRATE dosage: unknown. During the same period patient was treated with WARFARIN, SIMVASTATIN. Patient was hospitalized. Patient recovered.

FENOFIBRATE problem was reported by a Consumer or non-health professional from AUSTRALIA on Mar 19, 2007. Female patient, 65 years of age, was diagnosed with dyslipidaemia, atrial fibrillation, skin graft and was treated with FENOFIBRATE. After drug was administered, patient experienced the following problems/side effects: gastrointestinal haemorrhage, international normalised ratio increased. FENOFIBRATE dosage: unknown. During the same period patient was treated with WARFARIN, SIMVASTATIN. Patient was hospitalized. Patient recovered.

Consumer or non-health professional from FRANCE reported FENOFIBRATE problem on Mar 19, 2007. Female patient, 65 years of age, was diagnosed with dyslipidaemia, atrial fibrillation, mitral valve replacement and was treated with FENOFIBRATE. After drug was administered, patient experienced the following problems/side effects: haemarthrosis, international normalised ratio increased, melaena, normochromic normocytic anaemia, renal failure acute. FENOFIBRATE dosage: unknown. During the same period patient was treated with WARFARIN. Patient was hospitalized. Patient recovered.

FENOFIBRATE problem was reported by a Health Professional from FRANCE on Mar 20, 2007. Male patient, 40 years of age, was diagnosed with attention deficit/hyperactivity disorder and was treated with FENOFIBRATE. After drug was administered, patient experienced the following problems/side effects: irritability, mood swings. FENOFIBRATE dosage: unknown. During the same period patient was treated with STRATTERA, METHYLPHENIDATE, CILAZAPRIL. Patient recovered.

< Previous  Showing 151-194 of 194